Objective
Infectious diseases are one of main global health threats in the 21st century, with antibiotic resistance and specific threats such as Human Immunodeficiency Virus (HIV) and tuberculosis (TB) being of biggest concern to Europe. Vaccination is the most efficient approach to prevent infections. The efficiency of vaccines relies on the memory of the immune system. For decades the ability of an immune cell to “remember” a primary infection and subsequently to respond more effectively to the reinfection was solely attributed to adaptive immune cells. Recent findings showed that innate cells can also develop immune memory. In contrast to adaptive immune cells, the secondary response of innate cells is not pathogen-specific. In both cases the development of memory phenotype is accompanied by epigenetic changes in chromatin structure. These findings raise important questions: what decides about the ability of innate immune cells to mount memory phenotype and which factors trigger the secondary response? Does it lie in the type of receptors involved in the pathogen recognition or in chromatin modifications? “GammaDelta” project aims to answer these questions by studying gamma delta (gd) T cells which share characteristics of both innate and adaptive immune cells. Bacille Calmette-Guerin (BCG) vaccine developed to protect against TB induces memory gd T cells and it has been also shown to have a cross-protective effect. The role of memory gd T cells in this process has not been addressed. By applying traditional immunology techniques and newest high throughput sequencing based methodology I will examine the potential of BCG-induced memory gd T cells for the protective effects of the vaccine and which epigenetic mechanisms underlie this process. This will help to understand the interaction between immunological pathways and epigenetic modifications in innate immune memory, a knowledge necessary for the design of a new generation of more effective vaccines.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine immunology
- medical and health sciences health sciences infectious diseases RNA viruses HIV
- medical and health sciences clinical medicine pneumology tuberculosis
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
- medical and health sciences basic medicine pharmacology and pharmacy drug resistance antibiotic resistance
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-EF-RI - RI – Reintegration panel
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2017
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
53113 BONN
Germany
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.